20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
LB Pharmaceuticals Inc Common Stock (LBRX) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 49 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, LBRX reported $0M in revenue and ($25M) in net income.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | — | — | — |
| Gross Margin % | — | — | — | — | — |
| Operating Income (EBIT) | ($95M) | ($30M) | ($65M) | ($11M) | ($3M) |
| Operating Margin % | — | — | — | — | — |
| Net Income | ($86M) | ($25M) | ($63M) | ($6M) | ($14M) |
| Net Margin % | — | — | — | — | — |
| EBITDA | ($88M) | ($25M) | ($63M) | ($1M) | ($12M) |
| Earnings Per Share (EPS) | $-2.98 | $-1.00 | $-17.83 | $-1.77 | $-4.05 |
| Shares Outstanding (M) | 30M | 25M | 4M | 4M | 4M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | $0M | $0M | — | — | — | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($54M) | ($22M) | ($14M) | ($5M) | ($6M) | ($6M) | ($6M) | ($16M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($52M) | ($19M) | ($11M) | ($4M) | ($5M) | ($5M) | ($5M) | ($14M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($54M) | ($19M) | ($11M) | ($3M) | ($5M) | ($5M) | — | ($14M) |
| Earnings Per Share (EPS) | $-1.71 | $-0.67 | $-0.45 | $-0.14 | $-20.21 | $-20.21 | $-0.23 | $-0.63 |
| Shares Outstanding (M) | 30M | 28M | 25M | 25M | 0M | 0M | 22M | 22M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($82M) | ($35M) | ($53M) | ($12M) | ($3M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($83M) | ($35M) | ($54M) | ($12M) | ($3M) |
| FCF Margin % | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($38M) | ($23M) | ($18M) | ($3M) | ($6M) | ($8M) | ($6M) | ($22M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($38M) | ($23M) | ($18M) | ($3M) | ($6M) | ($8M) | ($6M) | ($22M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets | $362M | $313M | $34M | $46M | $21M |
| Cash & Cash Equivalents | $283M | $250M | $23M | $15M | $21M |
| Total Liabilities | $29M | $12M | $128M | $80M | $50M |
| Total Debt (Short + Long-Term) | $1M | $1M | $0M | $0M | $24M |
| Total Shareholders' Equity | $332M | $301M | ($95M) | ($34M) | ($29M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LBRX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms